Breast Cancer Treatment Market: Current Analysis and Forecast (2022-2030)

Breast Cancer Treatment Market: Current Analysis and Forecast (2022-2030)

The breast cancer treatment market is a highly competitive and dynamic space. It includes both traditional and emerging therapies, such as surgery, chemotherapy, radiation, hormone therapy, immunotherapy, and targeted therapies. The market is driven by the growing incidence of breast cancer cases, technological advancements, and the increasing demand for personalized treatments. For instance, according to World Health Organization, in 2020, there were 2.3 million women diagnosed with breast cancer globally. As of the end of 2020, there were 7.8 million women alive who were diagnosed with breast cancer in the past 5 years, making it the world’s most prevalent cancer.

Additionally, government initiatives to reduce the cost of healthcare and to provide better access to treatments are also driving the market. The market is segmented based on therapy, cancer type, end users, and geography. The key players in the market include Roche Holding AG, Novartis AG, Pfizer, Inc., Eli Lily and Company, AstraZeneca PLC, and Merck & Co., Inc.

The Breast Cancer Treatment Market is expected to grow at a strong CAGR of 9% during the forecast period.

• Based on therapy, the market is segmented into targeted therapy, surgery and radiation therapy, chemotherapy, immunotherapy, and others. Targeted therapy is dominating the market while immunotherapy segment is anticipated to witness the highest CAGR during the forecast period. In recent years, Immunotherapy is gaining popularity because of its high efficacy against metastatic breast cancer and several advanced immunotherapies got approval during the past few years. For instance, in July, 2021, Merck got FDA approval for Keytruda for the treatment of patients with high-risk early-stage triple-negative breast cancer in combination with chemotherapy as neoadjuvant treatment, then continued as single agent as adjuvant treatment after surgery.
• Based on cancer type, the market is segmented into Hormone Receptor and HER2+. Hormone receptor segment is dominating the market while HER2+ segment is anticipated to witness the highest CAGR during the forecast period. Increasing prevalence of HER2+ breast cancer along with improved clinical results are owing to the rapid growth of the HER2+ category. For Instance, as per the data of American Cancer Society and National Cancer Institute 2021, HER2+ breast cancer accounts for 14% of the total breast cancer cases. Moreover, continuous advancements in the HER2+ breast cancer therapeutics along with its role in combinational therapy is also expected to boost the breast cancer market.
• Based on end user, the market is segmented into hospitals, ambulatory surgical centers, specialty clinics, and others. Hospital sector is expected to dominate the market as they serve as primary healthcare facility while specialty clinics category is anticipated to witness the highest CAGR during the forecast period. The benefits of specialty clinics such as expertise and specialized care, Multidisciplinary approach, availability of supportive care services, continuity of breast cancer associated care etc. are the major reasons for the rapid growth of this segment during the forecast period. Moreover, specialty clinics can provide multiple facilities including diagnostic, treatment and management of breast cancer, which is also responsible for rapid growth of this sector in future.
• For a better understanding of the market adoption of the Breast Cancer Treatment industry, the market is analyzed based on its worldwide presence in the countries such as North America (U.S., Canada, and the Rest of North America), Europe (Germany, France, U.K., Italy, Spain, Rest of Europe), Asia-Pacific (China, Japan, India, and Rest of Asia-Pacific), Rest of World. North America dominated the Breast Cancer Treatment market in 2021. The increasing incidence of breast cancer cases among the population, the aging population, technological advancements, and increasing healthcare spending in several developed nations of North America region are the major factors driving the growth of the market.
• Some of the major players operating in the market include Novartis AG, Merck Co & Inc., Gilead, Pfizer Inc., Eli Lilly & Co., F. Hoffmann-La Roche, GlaxoSmithKline, AstraZeneca, Bristol Myers Squibb, and Seagen.

The Breast Cancer Treatment market is expected to grow at a strong CAGR of around ~9% during the forecast period.

The market is driven by the growing incidence of breast cancer cases, technological advancements, and the increasing demand for personalized treatments. For instance, according to World Health Organization, in 2020, there were 2.3 million women diagnosed with breast cancer globally. As of the end of 2020, there were 7.8 million women alive who were diagnosed with breast cancer in the past 5 years, making it the world’s most prevalent cancer.

Additionally, government initiatives to reduce the cost of healthcare and to provide better access to treatments are also driving the market. The market is segmented based on therapy, cancer type, end users, and geography.

The key players in the market include Roche Holding AG, Novartis AG, Pfizer, Inc., Eli Lily and Company, AstraZeneca PLC, and Merck & Co., Inc. Several M&As along with partnerships have been undertaken by these players to facilitate customers with hi-tech and innovative products/technologies.

Insights Presented in the Report

“Amongst therapy, the targeted therapy segment held a dominating share of the market in 2021”

Based on therapy, the market is segmented into targeted therapy, surgery and radiation therapy, chemotherapy, immunotherapy, and others. Targeted therapy is dominating the market while immunotherapy segment is anticipated to witness the highest CAGR during the forecast period. In recent years, Immunotherapy is gaining popularity because of its high efficacy against metastatic breast cancer and several advanced immunotherapies got approval during the past few years. For instance, in July 2021, Merck got FDA approval for Keytruda for the treatment of patients with high-risk early-stage triple-negative breast cancer in combination with chemotherapy as neoadjuvant treatment, then continued as single agent as adjuvant treatment after surgery.

“Amongst cancer type, the hormone receptor held the majority share of the market in 2021”

Based on cancer type, the market is segmented into Hormone Receptor and HER2+. Hormone receptor segment is dominating the market while HER2+ segment is anticipated to witness the highest CAGR during the forecast period. Increasing prevalence of HER2+ breast cancer along with improved clinical results are owing to the rapid growth of the HER2+ category. For Instance, as per the data of American Cancer Society and National Cancer Institute 2021, HER2+ breast cancer accounts for 14% of the total breast cancer cases. Moreover, continuous advancements in the HER2+ breast cancer therapeutics along with its role in combinational therapy is also expected to boost the breast cancer market.

“North America dominated the breast cancer treatment market in 2021”

North America dominated the Breast Cancer Treatment market in 2021. The increasing incidence of breast cancer cases among the population, the aging population, technological advancements, and increasing healthcare spending in several developed nations of North America region are the major factors driving the growth of the market.

Reasons to buy this report:

• The study includes market sizing and forecasting analysis validated by authenticated key industry experts.
• The report presents a quick review of overall industry performance at one glance.
• The report covers an in-depth analysis of prominent industry peers with a primary focus on key business financials, product portfolios, expansion strategies, and recent developments.
• Detailed examination of drivers, restraints, key trends, and opportunities prevailing in the industry.
• The study comprehensively covers the market across different segments.
• Deep dive regional level analysis of the industry.